Lipid Nanoparticle mRNA Delivery for Donor Platelet Protein Expression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for genetic modification of platelets are indirect, limited by scalability, transfection agent accessibility, and specificity, with existing transfection strategies failing to induce sufficient mRNA uptake and protein expression in platelets.

Innovation Solution

Lipid nanoparticle (LNP) compositions comprising mRNA encoding exogenous proteins and a specific lipid mixture, including ionizable cationic lipids, helper lipids, sterols, and PEG-lipid conjugates, enable efficient transfection and expression of exogenous proteins in platelet cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemical transfection methods such as lipofectamine are used, then mRNA delivery is attempted, but protein expression is not observed

Engineering Contradiction:

Improveprotein expressionVSAvoidtransfection method

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent modifies the chemical composition parameters of transfection reagents by incorporating ionizable cationic lipids with specific pKa values (6.5-8.5) and combining them with helper lipids, sterols, and PEG-lipid conjugates in optimized ratios. This parameter optimization enables reliable protein expression from delivered mRNA in platelets, resolving the failure of conventional lipofectamine-based methods.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If electroporation is used to deliver mRNA into platelets, then cargo uptake is enabled, but protein expression is not reliably demonstrated

Engineering Contradiction:

Improveprotein expressionVSAvoidtransfection approach

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces lipid nanoparticle complexes as an intermediary carrier that protects mRNA and facilitates its entry into platelets through endocytosis. These LNP intermediaries combine ionizable cationic lipids with mRNA to form stable complexes that can be internalized by platelets, enabling reliable protein expression without requiring complex electroporation devices.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Adaptability or versatility

If viral based transfection strategies are used, then DNA transfection is achieved, but they are not useful for direct donor platelet transfection

Engineering Contradiction:

Improvetransfection applicabilityVSAvoidprotein expression

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent replaces viral-based mechanical transfection strategies with a non-viral lipid nanoparticle system. This substitution eliminates the limitations of viral methods (nucleus requirement, synthesis capability) while achieving reliable mRNA delivery and protein expression in anucleate platelets through endocytic uptake and cytoplasmic release mechanisms.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

4Productivity

If indirect transfection of hematopoietic stem cell platelet precursors is used, then progenitor platelets with modified function are produced, but scalability is limited

Engineering Contradiction:

ImprovescalabilityVSAvoidtransfection process

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by directly transfecting isolated donor platelets with mRNA-encoded proteins before transfusion, rather than requiring lengthy in vivo or ex vivo differentiation processes. This direct approach enables rapid functional modification of platelets while maintaining scalability, as platelets can be transfected and transfused within a short time window.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The LNP compositions achieve minimal platelet activation and effective expression of exogenous proteins, expanding platelets' therapeutic potential for hemostasis and cell therapy applications.

Implementation Method 1

the at least one ionizable cationic lipid has a phase transition at a physiological pH

Methodology Applied

Scientific EffectPhase transition: Phase Change

Data Source

PatentUS20250313860A1Expression of exogenous proteins in donor platelets treated with lipid nanoparticles

Publication Date: 2025.10.09 THE UNIV OF BRITISH COLUMBIA

AI summary

The present disclosure provides a novel lipid nanoparticle (LNP) compositions useful for the transfection and expression of exogenous proteins in platelet cells. In particular, wherein the LNP composition comprises mRNA encoding the exogenous protein and a lipid mixture, and the lipid mixture comprises at least one ionizable cationic lipid, at least one helper lipid, a sterol, and at least one polyethylene glycol (PEG)-lipid conjugate. Further provided are use of the LNP compositions for transfection of platelets with messenger RNA encoding an exogenous protein and expression of the exogenous protein in the resulting transfected platelets.